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ABSTRACT
Background Mechanical thrombectomy (MT) is a time- 
sensitive emergency procedure for patients who had 
ischaemic stroke leading to improved health outcomes. 
Health systems need to ensure that MT is delivered to 
as many patients as quickly as possible. Using decision 
modelling, we aimed to evaluate the cost- effectiveness 
of secondary transfer by helicopter emergency medical 
services (HEMS) compared with ground emergency 
medical services (GEMS) of rural patients eligible for MT 
in England.
Methods The model consisted of (1) a short- run 
decision tree with two branches, representing secondary 
transfer transportation strategies and (2) a long- run 
Markov model for a theoretical population of rural 
patients with a confirmed ischaemic stroke. Strategies 
were compared by lifetime costs: quality- adjusted life 
years (QALYs), incremental cost per QALY gained and 
net monetary benefit. Sensitivity and scenario analyses 
explored uncertainty around parameter values.
Results We used the base case of early- presenting (<6 
hours to arterial puncture) patient aged 75 years who 
had stroke to compare HEMS and GEMS. This produced 
an incremental cost- effectiveness ratio (ICER) of £28 027 
when a 60 min reduction in travel time was assumed. 
Scenario analyses showed the importance of the 
reduction in travel time and futile transfers in lowering 
ICERs. For late presenting (>6 hours to arterial puncture), 
ground transportation is the dominant strategy.
Conclusion Our model indicates that using HEMS to 
transfer patients who had stroke eligible for MT from 
remote hospitals in England may be cost- effective 
when: travel time is reduced by at least 60 min 
compared with GEMS, and a £30 000/QALY threshold 
is used for decision- making. However, several other 
logistic considerations may impact on the use of air 
transportation.
INTRODUCTION
Mechanical thrombectomy (MT) is an endovas-
cular procedure that significantly improves func-
tional outcomes for patients who had ischaemic 
stroke caused by large artery occlusion by physically 
removing clot from the blocked artery in the brain.1 
Delivery of MT involves a complex care interven-
tion and pathway including specialist angiographic 
suites, a trained and experienced acute stroke and 
neuroendovascular teams with anaesthetic, critical 
care and preferably neurosurgical support. Recent 
research suggests that around 10% of patients who 
had stroke admitted to hospital in the UK would 
benefit from MT.2 It is a highly cost- effective treat-
ment when used either alone or in conjunction 
with intravenous thrombolysis.3 The effectiveness 
of both treatments is extremely time- dependent, 
with efficient emergency transportation deemed a 
critically important factor for achieving better long- 
term outcomes for patients.4 Currently, only urban- 
based neuroscience centres in England can deliver 
MT services, creating potential inequity of provi-
sion for rural patients—especially in areas with low 
population density that preclude a local thrombec-
tomy service ever being economically viable.
To improve equity of access for eligible rural 
patients served by smaller hospitals, the use of aero-
nautical transportation for secondary (interhospital) 
transfer has been proposed.5 Empirical research 
comparing the use of Air Ambulance (incorporating 
helicopter emergency medical services (HEMS)) 
with ground emergency medical services (GEMS) 
for secondary transfer of patients who had stroke 
has identified a variety of logistical, geographical 
and regulatory factors.6–8 The current international 
debate regarding the optimal paradigm for acute 
Key messages
What is already known on this subject
 ► Mechanical thrombectomy is a proven highly 
cost- effective procedure.
 ► Air transport has been used successfully 
for rural patients who had stroke eligible 
for mechanical thrombectomy in various 
jurisdictions.
What this study adds
 ► This modelling study indicated that secondary 
transfer of early- presenting rural patients 
who had stroke eligible for mechanical 
thrombectomy by air is an economically 
viable strategy if the time saved was 60 min 
and a £30 000/QALY threshold is used for 
decision- making.
 ► For late presenters, the value argument 
is less contentious as air transport is not 
cost- effective.
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(emergency) stroke services includes HEMS transportation.9 
From an NHS perspective, there is currently a need for the 
majority of regions in England to undertake secondary transfer 
by GEMS (ie, neuroscience centres take eligible patients with 
MT after initial assessment in a hyperacute stroke unit known as 
the drip- and- ship paradigm).
Given the under provision of neurointerventional teams and 
the geographically uneven distribution of neuroscience centres, 
NHS commissioners are beholden to examine service delivery 
options for providing MT, particularly those from remote loca-
tions.10 For many health systems such as the NHS, any newly 
proposed service delivery is accompanied by evidence of cost- 
effectiveness. This study aimed to evaluate whether secondary 
transfer (ie, drip- and- ship) by HEMS offers a cost- effective 
delivery option compared with GEMS using a decision analytic 
model for eligible rural patients who had stroke in England based 
on receiving optimal advanced imaging and treatment, prior to 
secondary transfer.
METHODS
Relevant NHS population
An ‘unavoidably small and remote’ hospital is defined by the 
NHS in England as a hospital serving a population of ≤2 00 000 
people who are domiciled more than 60 min travel by road from 
the nearest (major acute) hospital.11 We chose these hospitals, 
as they will never become MT centres—given that 1000–1200 
ischaemic stroke admissions per annum (or a catchment popula-
tion of ~1 000 000) is the likely minimum throughput required 
to sustain a stand- alone 24/7 MT centre’s experience and perfor-
mance in England.12 Entry into our model is based on patients 
already having a confirmed large artery occlusion ischaemic 
stroke after brain CT and (arch through brain) CT angiography 
examinations, treated with intravenous thrombolysis (where 
indicated) and deemed eligible for secondary transfer for MT.
The average age in the UK for someone to have a stroke is 72 
years for men and 78 years for women, according to Sentinel 
Stroke National Audit Programme (SSNAP) data.13 To demar-
cate MT- eligible patients based on time, we stratify into early 
and late presenters. In our base- case analysis, we define early 
presenters as patients receiving an arterial puncture within 360 
min from the time of onset of stroke. This cut- off point was 
identified from a meta- analysis of five randomised trials.14 15 We 
defined late presenters as those who had arterial puncture after 
360 min. Working backwards from puncture time there is a need 
to account for inevitable travel time from initial emergency call 
to reach remote hospital (assumed ≥150 min) and subsequent 
door- in to door- out at remote hospital (assumed ~60 min) and 
door- to- puncture time at MT centre (assumed ~30 min). There-
fore, we focus simulation modelling on puncture time between 
240 and 360 min.
Model structure and data sources
The economic model comprised a decision analytical model 
with two components: (1) a ‘short- run’ decision tree with 
two branches, representing secondary transfer transportation 
strategy (HEMS vs GEMS) and (2) a long- run Markov model 
with 3- month cycle length. The decision tree modelled the acute 
phase (up to 3 months) and the Markov model captured the life-
time health outcomes, incorporating the probability of a stroke 
reoccurrence. Health outcome states in stroke research typi-
cally use the modified Rankin Scale (mRS)16 that measures the 
degree of in/dependence in daily activities after a stroke. Thus, 
patients who had stroke with mRS levels 0, 1 or 2 at 90- day 
poststroke are considered to be functionally independent (no 
symptoms or slight disability). Those with mRS level 3, 4 or 5 
are considered dependent and have moderate to severe disability 
(mRS 6=deceased). On entering the Markov model, the health 
outcome probability of a patient was based on trial evidence that 
a relatively linear relationship exists between time to reperfu-
sion and 90- day mRS outcome.15 Transition probabilities after 
1 year from one health state (mRS) to another and 90- day mRS 
outcome probabilities from intravenous thrombolysis treatment 
are taken from a previous economic evaluation.17
To estimate the effect of a reduction in travel time, the results 
of an academic collaboration of seven randomised controlled 
trials was used for early presenters,14 15 whereas for late 
presenters, the DAWN trial provided the point estimate prob-
ability values of mRS scores and 90- day mortality.18 Influenced 
by recent geographical modelling12 and our estimates in change 
in travel time (mode change in travel time in rural England), 
our base- case analysis assumed a 60 min time to arterial punc-
ture reduction for HEMS (to 300 min) compared with GEMS 
(360 min). We also account for the number of patients eligible, 
probabilities of receiving MT backed by advanced imaging and 
not receiving MT because of spontaneous recanalisation based 
on previous research by this group.2 The annual mortality rate 
of patients who had stroke is 2.3 times19 than that of the age- 
adjusted, UK population without stroke.20 We further differen-
tiate by independent and dependent health state.
For complete cost details, see online supplemental appendix. 
Briefly, we adopted an NHS perspective and reported 2017–
2018 prices using a Bank of England inflation calculator. A 
microcosting study from five UK neuroscience centres provided 
the 24- hour procedural costs of MT (Balami, personal commu-
nication). The cost in each mRS health state was derived from a 
previous UK study3 with prices inflated to 2018 values. Depart-
ment of Health national schedule of reference costs (GEMS) 
and a survey of HEMS providers including Great North Air 
Ambulance service provided figures on transportation costs. The 
discount rate (3.5% per annum) accounted for future outcomes 
being valued less than present outcomes was applied. For specific 
rural hospitals that this model could apply to, ground- based travel 
time was calculated by Google maps and reduction in travel time 
by HEMS was assumed for illustration and discussion.
Outcome measure
Effectiveness was measured in quality- adjusted life Years (QALYs) 
gained from provision of MT using either transportation strategy. 
In the model, utility values were assigned to mRS outcome states 
of patients who had stroke21 and the QALY outcome of an indi-
vidual is the time spent in each state multiplied by the utility of 
each state.
Patient and public involvement
DB is a patient representative, part if the research team. DB was 
involved in all stages of the research process.
Data analysis strategy
In the base- case analysis on early presenters, deterministic 
analysis (point estimates) of parameter values are used in the 
cost- effectiveness (utility) decision model. Probabilistic sensi-
tivity analysis to characterise the uncertainty around the param-
eter values was conducted. All of the model parameters were 
jointly varied through credible ranges of values. Using Monte 
Carlo simulation, parameter values are randomly drawn from 
the assigned probability distributions and run 1000 times. 
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A cost- effectiveness acceptability curve was produced repre-
senting the probability that HEMS transfer will be cost- effective 
compared with GEMS transfer at a range of willingness- to- pay 
thresholds. We investigated alternative scenario analyses, such 
as alternative time- to- treatment intervals and reduction in travel 
time by 15 min increments. One- way sensitivity analysis of eligi-
bility for MT explored the impact of alternate time horizons 
(eg, 1–20 years). A secondary analysis of late presenters was also 
conducted.
Typically, the National Institute for Health and Care Excel-
lence (NICE) recommends an intervention such as a service, 
technology or drug for use in the NHS if the incremental cost- 
effectiveness ratio (ICER)—a measure of the additional cost per 
additional unit of health gained by a proposed intervention over 
current standard of care—is in the range of £20 000 to £30 000 
per QALY gained. Total costs and QALYs were modelled for 
both HEMS and GEMS to estimate the incremental cost per 
QALY gained. CHEERS checklist of reporting of economic eval-
uation was used. All analyses were carried out in TreeAge Pro 
Healthcare 2020 R1.1 (Morrisontown, New Jersey, USA). This 
was a modelling study using secondary data sources without 
personal identifiable data and deemed not to require ethical 
review.
RESULTS
We identified 10 small and remote hospitals in England that serve 
a combined population of approximately 2 million (see online 
supplemental appendix tables S1, S2). We estimated that up to 
a maximum of 501 early- presenting patients who had stroke 
per annum would clinically benefit from MT after secondary 
transfer using HEMS compared with GEMS (see online supple-
mental appendix table S3).
Model results
We based our analysis on the assumption that the mean age of 
patients was 75 years. To reflect heterogeneity of patients who 
had stroke, we assumed that age was normally distributed (age 
range: 60 to 92 years). Baseline estimates of decision tree param-
eters and the range for all probabilistic sensitivity analyses are 
provided in online supplemental appendix table S4. Similarly, 
estimates of Markov model parameters and the range for all 
probabilistic sensitivity analyses are shown in online supple-
mental appendix table S5.
In our base- case analysis, for a reduction in the time to reper-
fusion by 60 min in an early- presenting patient (360 to 300 
min), secondary transfer by HEMS for MT was associated with a 
higher probability of living independently at 90 days than GEMS 
Figure 1 Simplified structure of lifetime economic model with decision tree of transport options along with base- case values for first 3 months (L) 
and lifetime Markov model of health states. CTA, CT angiography; GEMS, ground emergency medical services; HEMS, helicopter emergency medical 
services; IV- tPA, intraveneous thrombolysis; LVO, large vessel occulsion; mRS, modified Rankin Scale; MT, mechanical thrombectomy.
Table 1 Mean lifetime cost- effectiveness analysis (base- case analysis of 1000 early presenter patients aged 75 years)
HEMS Ground- based ambulance
Mean 
cost (SE)
Mean
QALYs 
gained 
(SE)
Mean
cost
(SE)
Mean
QALYs 
gained
(SE)
Incremental
cost
(95% CI)
Incremental QALYs 
gained
(95% CI)
Incremental 
cost/QALY 
gained (ICER)
Incremental 
NMB
@20K/QALY
Incremental 
NMB
@30K/QALY
Deterministic
analysis
£60 132
(£7)
4.37
(0.00)
£56 328
(£6)
4.24
(0.00)
£3804
(£3800 to £3810)
0.14
(0.14 to 0.14)
£27 850 −£1073 +£294
Probabilistic analysis £60 743
(£319)
4.40
(0.03)
£56 959
(£308)
4.27
(0.03)
£3785
(£3700 to £3870)
0.14
(0.13 to 0.15)
£28 027 −£1084 +£266
Incremental NMB is calculated by first assuming a WTP (£20 000 or £30 000/QALY gained), then converting health benefits (QALYs) into the common metric of GBP. The cost 
associated with each transport strategy is then subtracted, resulting in the net benefit of each strategy expressed in the monetary units. The difference between the two is the 
incremental NMB, negative values favour GEMS and positive values favour HEMS. NMB = (E * WTP) – C.
Costs are rounded to nearest whole number. QALYs are rounded to second decimal place.
C, cost; E, effectiveness; GBP, Pound sterling; GEMS, ground emergency medical services; HEMS, helicopter emergency medical services ; ICER, incremental cost- effectiveness 
ratio; NMB, net monetary benefit; QALYs, quality- adjusted life years; WTP, willingness- to- pay threshold.
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(0.57 vs 0.53, respectively)—see figure 1. The base- case deter-
ministic and probabilistic results are presented in table 1. In deci-
sion analysis, the results of the probabilistic sensitivity analyses 
are more authoritative. Over a lifetime horizon, using HEMS 
as a secondary transportation strategy that enables patients to 
receive MT 60 min earlier results in greater QALYs gained (0.14) 
but is more costly (£3785). The ICER is £28 027 per QALY 
gained. The incremental net monetary benefit of the HEMS 
strategy is £266 for a threshold of £30 000 per QALY gained 
and favours the GEMS strategy for the lower bound of the NICE 
threshold (see online supplemental appendix figure S1 for the 
cost- effectiveness plane).
The cost- effectiveness acceptability curve (figure 2) shows the 
probability of HEMS being cost- effective for different levels of 
willingness- to- pay thresholds, compared with GEMS. At £30 
000 per QALY threshold, the HEMS strategy had 62.9% proba-
bility of being cost- effective.
Sensitivity and scenario analyses
Using the base- case values, the benefits of the HEMS strategy 
accrue over time increments with a 5- year time horizon for the 
benefit of HEMS transportation strategy for early presenters 
to be achieved (online supplemental appendix table S6). The 
results are highly sensitive to the proportion of patients in each 
strategy who are in the dependent state at 90 days, whom have 
increased annual medical costs to the NHS (first year costs in 
dependent state £22 706 and £8056 per annum in subsequent 
years).
When we altered the time of arterial puncture and reduc-
tions in travel time, ICERs are higher (see table 2 and online 
supplemental appendix table S7). This shows that a reduction 
of at least 60 min is required for the use of HEMS to be consid-
ered cost- effective at the upper threshold. The scenario (using 
base- case values) where those transferred are eligible for MT by 
HEMS but not by GEMS due to transport time saved, the ICER 
is £11,679/QALY gained. This assumes that those who travel 
by GEMS have the same 90- day outcome as those treated with 
thrombolysis.
Varying the proportion of patients eligible for thrombectomy 
captures the effect on the ICER if interhospital transfer was 
futile (table 3). Essentially, the probability that transfer results 
in thrombectomy occurring is important to the viability of 
Figure 2 Cost- effectiveness acceptability curve for early presenters by transportation strategy. GEMS, ground emergency medical services; HEMS, 
helicopter emergency medical services; QALY, quality- adjusted life years.
Table 2 Scenario analysis for early presenters based on travel time difference
HEMS vs GEMS Air (pInd; pDep; pDead) GBA (pInd; pDep; pDead) ICER % CE at £20k/QALY
Travel time (mins) 60 min difference
300 vs 360 0.57; 0.36; 0.07 0.53; 0.39; 0.08 £28 027 14.8 62.9
270 vs 330 0.59; 0.35; 0.06 0.53; 0.39; 0.08 £26 318 17.4 70.6
240 vs 300 0.61; 0.33; 0.06 0.57; 0.36; 0.07 £27 415 18.7 64.7
180 vs 240 0.64; 0.30; 0.06 0.61; 0.33; 0.06 £41 370 14.1 26.2
Travel time (min) 45 min difference
315 vs 360 0.56; 0.37; 0.07 0.53; 0.39; 0.08 £37 545 8.3 25.4
285 vs 330 0.58; 0.35; 0.07 0.55; 0.37; 0.08 £35 266 9.4 27.7
255 vs 300 0.60; 0.34; 0.06 0.57; 0.36; 0.07 £34 864 10.8 29.1
195 vs 240 0.63; 0.31; 0.06 0.61; 0.33; 0.06 £58 414 8.8 16.6
CE, cost- effective; GBA, ground- based ambulance; GEMS, ground emergency medical services; HEMS, helicopter emergency medical services; ICER, incremental cost- effectiveness 
ratio; QALY, quality- adjusted life year.
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providing the HEMS service for eligible rural patients who had 
stroke.
The linear assumption of time- to- reperfusion and 90- day mRS 
score for early presenters cannot be applied to late presenters. 
Instead, for late presenters we used results from the more recent 
DAWN trial18 which suggested that clinical benefits of MT could 
occur up to 24 hours from onset of stroke. The probability of 
90- day independence is 0.38, 0.48 for dependence and 0.14 
for death.22 We assumed that the probability of independence 
increased by two percentage points and dependence decreased 
by two percentage points if transferred by HEMS. However, this 
is a very much smaller number of patients than early presenter 
category comprising only approximately 12% of the total 
number eligible for MT.2 Unsurprisingly, given that there is not 
the same relationship between time of onset and outcome in late 
presenters with a favourable imaging profile (and thus eligible 
for MT), model results indicated that HEMS is dominated by 
GEMS for late presenters (online supplemental appendix table 
S9). For late presenters, HEMS is not cost- effective at any 
acceptable cost- effectiveness threshold to NHS commissioners 
(online supplemental appendix figures S2,3).
DISCUSSION
Using the most relevant data, we show the range of cost- 
effectiveness metrics for consideration of secondary transfer by 
HEMS from small and remote English hospitals to MT- enabled 
neuroscience centres, available to NHS commissioners. In our 
base- case analysis, we consider a reduction of 60 min travel 
time with an ICER of £28 027. Using the standard NICE cost- 
effectiveness threshold (£20–£30 000 per QALY), this would 
suggest that at the lower bound that the service would not be 
cost- effective but would be within the upper bound. Our sensi-
tivity analysis showed that at least 60 min reduction in travel time 
is the minimum necessary for HEMS transportation to repre-
sent value- for- money at NICE’s upper bound of willingness- 
to- pay thresholds (£30 000 per QALY). In the scenario of late 
presenters, using land transport for secondary transfer domi-
nated. In lieu of real- world evidence or a randomised controlled 
trial, these analyses may be informative to decision- making 
regarding the optimal service configuration for MT in England, 
while addressing the critical issue of equity of access in smaller 
populations more remote from existing (and indeed any future) 
MT- enabled neuroscience centres.
Empirical international studies show a mixed picture of using 
HEMS for secondary transfer of patients who had stroke.6–9 23 
In our modelling study, we only consider the drip- and- ship para-
digm. In Alberta, Canada, a Health Technology Optimisation 
Analysis, incorporating cost- effectiveness analysis, reported the 
‘optimal strategy’ as a combination of paradigms (ie, mother-
ship—direct transfer to MT centre, drip- and- ship), transport 
modes (ie, by ground, by flight) and treatment metric options 
(ie, minimum time to thrombolysis, minimum time to throm-
bectomy) from a clinical outcomes and health system perspec-
tive.9 Research incorporating such factors in England would 
be advantageous; however, modelling this is far more complex 
as there are 24 existing MT- enabled neuroscience centres in 
England compared with only two in Alberta. Based on latest 
SSNAP data, currently ~1200 MT procedures were delivered in 
2018/2019 throughout the UK with the overwhelming majority 
in England.10 Out of the estimated 8000 patients eligible for MT 
in England, cost- effectiveness of HEMS provision pertains to 
a relatively small number of patients (maximum n≃500). The 
optimal configuration will always involve a trade- off between 
minimising time to treatment and sustaining local service 
provision.12
Our modelling work is predicated by the assumption that air 
transfer will reduce transport time. We then link these hypo-
thetical time savings by HEMS to cost- effectiveness based on 
expected 90- day outcome. However, delays occur using either 
mode of transport.8 Again, empirical evidence of using HEMS in 
the NHS service would be beneficial for commissioners to make 
informed decisions about the potential benefit of secondary 
transfers for MT. The absence of underpinning HEMS efficiency 
evidence is a limitation of our modelling work. Our research 
premise was based on the NHS definition of remote hospitals. 
However, there are additional English hospitals which do not 
fully meet the NHS England definition of ‘small and remote’ but 
are 60–90 min away from a neuroscience centre via GEMS where 
these findings might also apply, particularly if circumstances and 
population size preclude the development of a viable local MT 
Table 3 One- way sensitivity analysis of eligibility for MT
Eligibility
for
MT
Helicopter emergency medical 
services
Ground emergency
medical services
Incremental cost
(95% CI)
Incremental QALYs 
gained
(95% CI)
Incremental 
cost/QALY 
gained (ICER)
% CE at
£20k/QALY
% CE at
£30k/QALY
Mean
cost
(SE)
Mean
QALYs gained (SE)
Mean
cost
(SE)
Mean
QALYs gained 
(SE)
0.4 £56 042
(£314)
3.76
(0.03)
£53 284
(£308)
3.75
(0.03)
£2759
(£2710 to £2800)
0.01
(0.01 to 0.02)
£291 127 3.3 10.5
0.5 £56 897
(£314)
3.88
(0.03)
£53 952
(£308)
3.85
(0.03)
£2945
(£2890 to £3000)
0.03
(0.03 to 0.03)
£91 167 4.3 14.6
0.6 £57 752
(£315)
3.99
(0.03)
£54 620
(£307)
3.94
(0.03)
£3132
(£3070 to £3190)
0.06
(0.05 to 0.07)
£56 801 5.1 20.2
0.7 £58 606
(£316)
4.11
(0.03)
£55 288
(£307)
4.03
(0.03)
£3318
(£3250 to £3380)
0.08
(0.07 to 0.09)
£42 562 7.4 27.4
0.8 £59 461
(£317)
4.23
(0.03)
£55 956
(£307)
4.13
(0.03)
£3505
(£3430 to £3580)
0.10
(0.09 to 0.11)
£34 773 9.7 37.5
0.9 £60 316
(£318)
4.34
(0.03)
£56 625
(£307)
4.22
(0.03)
£3691
(£3610 to £3770)
0.12
(0.11 to 0.13)
£29 860 12.9 55.1
1.0 £61 171
(£320)
4.46
(0.03)
£57 293
(£308)
4.31
(0.03)
£3898
(£3790 to £3970)
0.15
(0.14 to 0.16)
£26 479 18.2 68.9
CE, cost- effective; ICER, incremental cost- effectiveness ratio; MT, mechanical thrombectomy; QALY, quality- adjusted life year.
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centre. Alternatively, the concept of bringing the stroke treatment 
to the patient referred to as the drip- and- drive model piloted in 
Germany involves the neurointerventionist being driven by road 
to the local hospital.24 However, this requires substantial capital 
(angiographic equipment) and supporting staff investment in the 
local hospitals plus appreciably larger neurointerventional teams 
than either a drip- and- ship or mothership model24 and is not 
currently realistic in England.
Reducing futile secondary transfer is imperative. Our base- case 
model employed a strict eligibility criterion based on advanced 
imaging in rural hospitals. Our sensitivity analysis showed that 
90% of patients need to receive thrombectomy for the HEMS 
transportation strategy to be considered cost- effective. In reality, 
even among patients initially deemed good candidates for EVT 
at the rural hospital, the possibility of futile transfer, either 
due to worsening infarct or opening of the vessel by alteplase, 
exists. Also, not all patients with potential thrombectomy will be 
eligible for flight because of individual characteristics. However, 
concerns around the potential detrimental impact of HEMS on 
a patient’s clinical status have not been substantiated.6 Never-
theless, HEMS has some intrinsic limitations due to operational 
aeronautical factors.5 HEMS is more vulnerable to weather 
conditions, aircraft availability and have more restrictive opera-
tional hours (10 to 16 hours a day in good weather) than GEMS. 
An independent report to the Department of Health from 2003 
highlighted that unavailability in English services due to weather 
was approximately 2% of normal flying time.25 Another factor 
that NHS commissioners will need to consider is the governance 
of air ambulance, as many are charities and not all are under 
direct NHS deployment.
For the 10 small and remote hospitals across England that this 
analysis applies to, we assumed time savings by the predomi-
nantly charity- funded HEMS providers. Based on the practical 
and logistical considerations outlined, we feel that contracting 
on a fee- for- service basis, rather than capital investment, would 
likely be more appealing to NHS commissioners concerned 
about budget impact and affordability.
CONCLUSION
Helicopter transportation, especially for rural patients, may 
have a role to play in the national service configuration of stroke 
services in England. This role should build on the current system 
to improve effectiveness and outcomes for patients who had 
stroke irrespective of treatment they receive.
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